Actigraphic Analysis of Treatment Response
Sleep Disorders, Circadian Rhythm, Insomnia, Psychomotor Agitation
About this trial
This is an interventional health services research trial for Sleep Disorders, Circadian Rhythm focused on measuring Kabuki Syndrome, Actigraphy, Treatment Response Measurement
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of Kabuki Syndrome
- Medication Naive
- Single subject preparing to receive pharmacological intervention
Exclusion Criteria:
- Inability to wear actigraphy device
Sites / Locations
- Child Psychopharmacology Institute
Arms of the Study
Arm 1
Experimental
Sleep and Activity by Treatment Condition
Actigraphic measurements were obtained by attaching an actigraphic watch device to the child's non-dominant wrist. The measurements will include three separate three week periods beginning with a baseline period and the period in which the child's pharmacological treatment was initiated. Two additional three week actigraphic measurement periods will occur at 22 months post-baseline period and at 23 months post-baseline period. The resulting five treatment conditions were: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.). Sleep and activity will be evaluated by treatment conditions.